Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Hillevax Inc (HLVX)

Hillevax Inc (HLVX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 536,521
  • Shares Outstanding, K 33,345
  • Annual Sales, $ 0 K
  • Annual Income, $ -102,410 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.87
Trade HLVX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -1.31
  • Number of Estimates 3
  • High Estimate -0.68
  • Low Estimate -2.27
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.13%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.70 +2.29%
on 12/07/22
22.68 -29.19%
on 11/11/22
-5.05 (-23.92%)
since 11/08/22
3-Month
15.10 +6.36%
on 10/12/22
24.42 -34.23%
on 09/14/22
-1.05 (-6.14%)
since 09/08/22

Most Recent Stories

More News
Here's Why "Trend" Investors Would Love Betting on HilleVax, Inc. (HLVX)

HilleVax, Inc. (HLVX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through...

HLVX : 16.10 (+0.06%)
Wall Street Analysts Predict a 67% Upside in HilleVax, Inc. (HLVX): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 67% in HilleVax, Inc. (HLVX). While the effectiveness of this highly sought-after metric is questionable, the positive...

HLVX : 16.10 (+0.06%)
3 IPO Stocks That You Want to Own

This down market is giving us some really intriguing stocks at cheap prices.

AMLX : 37.75 (+0.61%)
HLVX : 16.10 (+0.06%)
DCGO : 6.65 (-1.77%)
TAK : 14.81 (+0.82%)
HilleVax Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress

BOSTON, Aug. 10, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and...

HLVX : 16.10 (+0.06%)
HilleVax Announces Results from 5-Year Clinical Study Supporting Long-Term Immunogenicity of HIL-214 Norovirus Vaccine Candidate

Pan-Ig and HBGA blocking antibody responses persisted to year 5 No adverse events deemed related to HIL-214 BOSTON, July 20, 2022 (GLOBE NEWSWIRE)...

HLVX : 16.10 (+0.06%)
HilleVax Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress

Initiated Phase 2b Clinical Trial of HIL-214 Vaccine Candidate for the Prevention of Norovirus-Related Acute Gastroenteritis in Infants (NOR-212) ...

HLVX : 16.10 (+0.06%)
HilleVax Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and...

HLVX : 16.10 (+0.06%)
Stock Market This Week: Five Themes To Watch

Following a volatile series of sessions, investors are entering the month of May with several reasons to be cautious.

HLVX : 16.10 (+0.06%)
MPC : 109.55 (+0.50%)
VWAGY : 18.6900 (-0.80%)
CNK : 12.46 (+3.66%)

Business Summary

HilleVax Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Its initial program, HIL-214, is a virus-like particle based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection....

See More

Key Turning Points

3rd Resistance Point 16.99
2nd Resistance Point 16.66
1st Resistance Point 16.37
Last Price 16.10
1st Support Level 15.75
2nd Support Level 15.42
3rd Support Level 15.13

See More

52-Week High 24.42
Fibonacci 61.8% 18.11
Fibonacci 50% 16.16
Last Price 16.10
Fibonacci 38.2% 14.21
52-Week Low 7.90

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar